No specific description provided

This product is a β-lactamase-stable cephalosporin bactericidal antibiotic that works by blocking the synthesis of the main cell wall polymer, peptidoglycan. Because it can quickly penetrate the bacterial cell wall and bind to the target enzyme (penicillin binding protein) with high affinity, it can kill a wide spectrum of Gram-negative and Gram-positive pathogens at low concentrations.

Ceftriaxone is a long-acting, broad-spectrum cephalosporin that produces antibacterial effects by inhibiting the synthesis of cell walls. It has a strong bactericidal effect on both Gram-positive and Gram-negative bacteria. It is highly stable to beta-lactamase (including penicillinase and cephalosporinase). In vitro and clinical trials have shown that ceftriaxone sodium has high antibacterial activity against the following Gram-negative bacilli: Escherichia coli, Klebsiella, Proteus mirabilis, indole-positive Proteus, Salmonella, Shigella and other r/Enterobacteriaceae and Haemophilus influenzae; it also has good antibacterial effects on Gram-negative cocci such as meningococci and gonococci; Gram-positive cocci such as pneumococci, Streptococcus pyogenes, Streptococcus viridans, and Streptococcus bovis are all sensitive to this product; it also has a certain antibacterial effect on Staphylococcus aureus, but the antibacterial effect is poorer than that of the above-mentioned Gram-positive cocci. Pseudomonas aeruginosa and Acinetobacter are less sensitive to this product. It also has antibacterial activity against some anaerobic bacteria such as Bacteroides fragilis, Clostridium, and Peptococcus.

Ceftriaxone is a long-acting, broad-spectrum cephalosporin that produces antibacterial effects by inhibiting the synthesis of cell walls. It has a strong bactericidal effect on both Gram-positive and Gram-negative bacteria. It is highly stable to beta-lactamase (including penicillinase and cephalosporinase). In vitro and clinical trials have shown that ceftriaxone sodium has high antibacterial activity against the following Gram-negative bacilli: Escherichia coli, Klebsiella, Proteus mirabilis, indole-positive Proteus, Salmonella, Shigella and other r/Enterobacteriaceae and Haemophilus influenzae; it also has good antibacterial effects on Gram-negative cocci such as meningococci and gonococci; Gram-positive cocci such as pneumococci, Streptococcus pyogenes, Streptococcus viridans, and Streptococcus bovis are all sensitive to this product; it also has a certain antibacterial effect on Staphylococcus aureus, but the antibacterial effect is poorer than that of the above-mentioned Gram-positive cocci. Pseudomonas aeruginosa and Acinetobacter are less sensitive to this product. It also has antibacterial activity against some anaerobic bacteria such as Bacteroides fragilis, Clostridium, and Peptococcus.

Piperacillin is a semi-synthetic penicillin antibiotic with a broad-spectrum antibacterial effect. It has good antibacterial effects on Enterobacteriaceae such as Escherichia coli, Proteus, Serratia, Klebsiella, Enterobacter, Citrobacter, Salmonella and Shigella, as well as other Gram-negative bacteria such as Pseudomonas aeruginosa, Acinetobacter, Haemophilus influenzae and Neisseria. It also has certain antibacterial activity against Enterococci, Group A and Group B hemolytic streptococci, Streptococcus pneumoniae and Staphylococci that do not produce penicillinase. Many anaerobic bacteria, including Bacteroides fragilis and Clostridium, are also sensitive to piperacillin. The mechanism of action of piperacillin is to exert a bactericidal effect by inhibiting bacterial cell wall synthesis.